

## Hikma Pharmaceuticals PLC

### Results of 2023 Annual General Meeting

**LONDON, 28 April 2023** Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting (“AGM”), held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN and virtually on 28 April 2023 commenced at 11 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 20 were passed as ordinary resolutions and Resolutions and 21 to 24 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA’s Electronic Submission System and will be available from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 16 March 2023) is set out below. The number of Ordinary Shares in issue on 27 April 2023 was 233,821,373. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 220,988,140.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2022 report and accounts	173,404,465	99.99	18,525	0.01	173,422,990	1,486,671
2. To approve a final dividend of 37 cents per share	174,904,572	100.00	3,407	0.00	174,907,979	1,682
3. To re-appoint PricewaterhouseCoopers LLP as Auditor	173,901,259	99.43	1,004,451	0.57	174,905,710	3,951
4. To authorise the Audit Committee to determine the remuneration of the Auditor	174,902,468	100.00	4,247	0.00	174,906,715	2,946
5. To elect Laura Balan as a Director of the Company	174,560,635	99.80	345,653	0.20	174,906,288	3,373
6. To elect Victoria Hull as a Director	172,985,379	98.90	1,920,959	1.10	174,906,338	3,322
7. To elect Dr Deneen Vojta as a Director	174,145,610	99.57	759,059	0.43	174,904,669	4,992
8. To re-elect Said Darwazah as a Director	167,417,879	95.79	7,363,833	4.21	174,781,712	127,949
9. To re-elect Mazen Darwazah as a Director	166,197,026	95.09	8,584,687	4.91	174,781,713	127,948
10. To re-elect Patrick Butler as a Director	169,789,166	97.08	5,115,966	2.92	174,905,132	4,529
11. To re-elect Ali Al-Husry as a Director	173,667,423	99.36	1,114,623	0.64	174,782,046	127,615
12. To re-elect John Castellani as a Director	174,135,021	99.56	770,111	0.44	174,905,132	4,529
13. To re-elect Nina Henderson as a Director	172,945,073	98.88	1,961,390	1.12	174,906,463	3,198
14. To re-elect Cynthia Flowers as a Director	174,560,963	99.80	345,325	0.20	174,906,288	3,373

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
<b>15.</b> To re-elect Douglas Hurt as a Director	174,135,291	99.56	769,811	0.44	174,905,102	4,559
<b>16.</b> To receive and approve the annual report on Remuneration	169,944,824	97.16	4,959,681	2.84	174,904,505	5,145
<b>17.</b> To approve the Directors' Remuneration Policy	171,820,411	98.24	3,085,011	1.76	174,905,422	4,239
<b>18.</b> To authorise the Directors to allot shares and grant rights to subscribe for shares	169,738,766	97.05	5,168,220	2.95	174,906,986	2,674
<b>19.</b> To approve the Long-Term Incentive Plan 2023	172,742,090	98.76	2,164,458	1.24	174,906,548	3,113
<b>20.</b> To approve the Deferred Bonus Plan 2023	173,885,322	99.42	1,021,749	0.58	174,907,071	2,590
<b>21.</b> To authorise the disapplication of pre-emption rights (General)	166,689,167	95.30	8,217,162	4.70	174,906,329	3,331
<b>22.</b> To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment)	159,504,839	91.19	15,401,490	8.81	174,906,329	3,331
<b>23.</b> To authorise the Company to purchase Ordinary Shares	173,797,944	99.42	1,018,079	0.58	174,816,023	93,638
<b>24.</b> To authorise the Company to hold general meetings on not less than 14 clear days' notice	169,319,647	96.81	5,588,186	3.19	174,907,833	1,828

### **Senior Independent Director**

At the conclusion of the AGM, as reported in our 2022 Annual Report, Patrick Butler stepped down as Senior Independent Director, Chair of the Nomination and Governance Committee and as a member of the Audit Committee and Remuneration Committee. Patrick Butler will remain on the Board as a non-independent Non-Executive Director for one further year, stepping down no later than the 2024 AGM. Victoria Hull was appointed as Senior Independent Director and Chair of the Nomination and Governance Committee.

### **Declaration of final dividend**

The dividend of 37 cents per share will be paid on 5 May 2023 to shareholders on the register on 24 March 2023. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.2532 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa \$1 to 0.71JD.

- ENDS -

**Enquiries:**

**Hikma Pharmaceuticals PLC**

Hussein Arkhagha

Chief Counsel and Company Secretary

+44 20 7399 2670